• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Microbiology >Global Assessment of Antimicrobial Susceptibility among Gram-Negative Organisms Collected from Pediatric Patients between 2004 and 2012: Results from the Tigecycline Evaluation and Surveillance Trial
【24h】

Global Assessment of Antimicrobial Susceptibility among Gram-Negative Organisms Collected from Pediatric Patients between 2004 and 2012: Results from the Tigecycline Evaluation and Surveillance Trial

机译：2004年至2012年间从儿科患者中收集的革兰氏阴性菌对抗生素敏感性的全球评估：Tigecycline评估和监测试验的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Tigecycline Evaluation and Surveillance Trial (TEST) was designed to monitor susceptibility to commonly used antimicrobial agents among important pathogens. We report here on susceptibility among Gram-negative pathogens collected globally from pediatric patients between 2004 and 2012. Antimicrobial susceptibility was determined using guidelines published by the Clinical and Laboratory Standards Institute (CLSI). Most Enterobacteriaceae showed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to minocycline, and susceptibility rates were highest in North America, Europe, and Asia/Pacific Rim. Amikacin was the most active agent against Pseudomonas aeruginosa (90.4% susceptibility), with susceptibility rates being highest in North America. Extended-spectrum β-lactamases (ESBLs) were reported for 11.0% of Escherichia coli isolates and 24.2% of Klebsiella pneumoniae isolates globally, with rates reaching as high as 25.7% in the Middle East and >43% in Africa and Latin America, respectively. Statistically significant (P < 0.01) differences in susceptibility rates were noted between pediatric age groups (1 to 5 years, 6 to 12 years, or 13 to 17 years of age), globally and in some regions, for all pathogens except Haemophilus influenzae. Significant (P < 0.01) differences were reported for all pathogens globally and in most regions, considerably more frequently, when pediatric and adult susceptibility results were compared. Amikacin, tigecycline, and the carbapenems were active in vitro against most Gram-negative pathogens collected from pediatric patients; A. baumannii and P. aeruginosa were susceptible to fewer antimicrobial agents. Susceptibility rates among isolates from pediatric patients were frequently different from those among isolates collected from adults.
机译：Tigecycline评价和监视试验（TEST）旨在监测重要病原体中常用抗菌剂的敏感性。我们在此报告了2004年至2012年间从儿科患者中全球收集的革兰氏阴性病原体的药敏性。抗菌药敏性是根据临床和实验室标准协会（CLSI）发布的指南确定的。大多数肠杆菌科细菌对丁胺卡那霉素，替加环素和碳青霉烯（亚胺培南和美洛培南）的敏感性很高（> 95％）。 90.8％的鲍曼不动杆菌分离株对米诺环素敏感，在北美，欧洲和亚太环太平洋地区敏感性最高。阿米卡星是铜绿假单胞菌最有效的药物（药敏率为90.4％），在北美的药敏率最高。据报道，全球范围内大肠埃希菌的11.0％和肺炎克雷伯菌的24.2％出现了广谱β-内酰胺酶（ESBLs），中东的比率高达25.7％，非洲和拉丁美洲的比率高达43％。 。在全球和某些地区，小儿年龄段（1至5岁，6至12岁或13至17岁）之间的药敏率差异有统计学意义（ P <0.01），除流感嗜血杆菌外的所有病原体。当比较儿科和成人药敏结果时，全球和大多数地区的所有病原体均报告有显着差异（ P <0.01）。阿米卡星，替加环素和碳青霉烯类药物在体外对从儿科患者中收集的大多数革兰氏阴性病原体具有活性。鲍曼不动杆菌和铜绿假单胞菌对较少的抗微生物剂敏感。小儿患者分离株的易感性经常与成人分离株的易感性不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号